DocWire News Editors

DocwireNews

In treatment-na&iuml;ve patients with chronic lymphocytic leukemia (CLL) and those with relapsed/refractory (R/R) CLL, sequential treatment with bendamustine debulking followed by obinutuzumab and idelalisib was associated with durable responses and undetectable minimal residual disease (MRD) levels, according to results from the CLL2-BCG trial presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition.Results from the open-label, multicenter CLL2-BCG trial were presented by Paula Cramer of the University Hospital in Cologne. The trial enrolled 48 patients with high-risk CLL who had an absolute lymphocyte count of 25,000/&micro;l or more and/or lymph nodes measuring 5 cm or greater.The investigators administered two cycles of bendamustine 70 mg/m&sup2; as debulking (n=38). During the induction phase, patients received obinutuzumab 1,000 mg on days one, eight, and 15 of cycle one and day one of cycles two through six (n=33). Twice-daily idelalisib 150 mg was added to this obinutuzumab regimen in cycle two. The investigators continued to administer daily idelalisib in addition to obinutuzumab every three months during the maintenance phase until patients achieved an MRD-negative complete response for up to 24 months (n=27).The median age of the population was 66 years. A total of 16 patients were treatment-na&iuml;ve, and 32 had experienced R/R CLL after a median of two prior lines of therapy.Overall response rates in the full analysis set and the per-protocol analysis were 80% and 85%, respectively. Approximately 23% of patients in the full analysis and 27% of patients in the per-protocol analysis achieved undetectable MRD levels. The median progression-free survival was 44 months in treatment-na&iuml;ve patients and 33 months in R/R CLL patients. Although the median overall survival (OS) was not reached for treatment-na&iuml;ve patients, the median OS was 46 months in patients with R/R disease.There was a total of 603 adverse events reported in the overall cohort, with 52% of events related to the study drug. Deaths occurring in this study were due to infections (n=7), cardiac arrest (n=1), and Richter&rsquo;s transformation (n=1).&ldquo;In light of the current, alternative therapeutic options, the BCG [trial] regimen &hellip; should be used with caution,&rdquo; the authors noted, &ldquo;but represents an alternative treatment option if ibrutinib and venetoclax have failed.&rdquo;

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Bendamustine with Obinutuzumab and Idelalisib Lead to Promising Responses in CLL

ASH Annual Meeting 2020

In treatment-naïve patients with chronic lymphocytic leukemia (CLL) and those with relapsed/refractory (R/R) CLL, sequential treatment with bendamustine debulking followed by ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe